EuroPCR 2021: Late-Breaking Science Collection

Published: 22 June 2021

  • Views:

    Views Icon 1291
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

In part 1 of this video series, Prof Nicolas Van Mieghem and Dr Joost Daemen host our review series View from the Thoraxcenter. This provides a concise analysis of the highlights of EuroPCR 2021’s Late-Breaking Trials.

 

The Expert Interviews featured in part 2 provide a short, accessible overview of some selected trials presented at EuroPCR 2021. These videos focus on each study’s design, results and impact on future practice. Some highlights of these interviews include an overview of the Portico NG study from Prof Lars Søndergaard and an insightful discussion of TAVR for Bicuspid Aortic Valve Stenosis in a low-risk patient population by Dr Raj Makkar.

Faculty Biographies

Lars Søndergaard

Lars Søndergaard

Professor Lars Søndergaard is a consultant cardiologist at Rigshospitalet – Copenhagen, Denmark. Professor of Cardiology at University of Copenhagen, he published over 300 peer reviewed articles, and more than 15 textbook chapters. His research interests are focused on adults with congenital heart diseases and catheter-based heart valve interventions, as well as congenital and structural heart diseases. He led the first-in-human transcatheter mitral valve implantation (CardiAQ) in 2012 and he actively participated to several trials, including NOTION (transcatheter vs. surgical aortic valve replacement in patients with aortic stenosis and low surgical risk), and the REDUCE randomised trial (PFO vs anti-platelet therapy after cryptogenic stroke).

View full profile